Admission to Trading
Summary by AI BETAClose X
Issued: 23 March 2026, London UK
Admission to trading
In conformity with PRM 1.6.4R, GSK plc notifies the market that ordinary shares of 31¼ pence each ('Ordinary Shares') have been admitted to trading as set out in the table below. The Ordinary Shares have been admitted to trading under existing block listing admissions of Ordinary Shares in connection with the "GlaxoSmithKline plc Share Save Plan 2012 and 2022".
|
1a |
Issuer name
|
GSK plc |
|
1b |
Issuer LEI
|
5493000HZTVUYLO1D793 |
|
2 |
Regulated market on which the securities have been admitted to trading
|
London Stock Exchange - Main Market |
|
3 |
Name, type and ISIN of the securities |
Ordinary Shares of 31¼ pence each
ISIN: GB00BN7SWP63
|
|
4 |
Number of further securities admitted to trading covered by this notification
|
96,525 |
|
5 |
Total number of securities admitted to trading following admission
|
4,316,176,278 |
|
6 |
Fungibility
|
Fully fungible with existing Ordinary Shares |
|
7 |
Date range covered by the notification |
23 January 2026 - 20 March 2026
|
|
8 |
Prospectus information |
N/A
|
V A Whyte
Company Secretary
23 March 2026
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
